DrugPatentWatch Database Preview
Drugs in Development Information for Fenebrutinib
» See Plans and Pricing
What is the drug development status for Fenebrutinib?
Fenebrutinib is an investigational drug.
There have been 5 clinical trials for Fenebrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 17th 2020.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Multiple Sclerosis, Chronic Progressive. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].
There are six US patents protecting this investigational drug and ninety-eight international patents.
Summary for Fenebrutinib
| US Patents | 6 |
| International Patents | 98 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-12-17) |
| Vendors | 20 |
Recent Clinical Trials for Fenebrutinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
| Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | Phase 3 |
| A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis | Hoffmann-La Roche | Phase 3 |
Clinical Trial Summary for Fenebrutinib
Top disease conditions for Fenebrutinib
Top clinical trial sponsors for Fenebrutinib
US Patents for Fenebrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fenebrutinib | Start Trial | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Fenebrutinib | Start Trial | Process for preparing BTK inhibitors | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Fenebrutinib | Start Trial | Heteroaryl pyridone and aza-pyridone compounds | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Fenebrutinib | Start Trial | Heteroaryl pyridone and aza-pyridone compounds | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fenebrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fenebrutinib | Argentina | AR107751 | 2036-02-29 | Start Trial |
| Fenebrutinib | Australia | AU2017227929 | 2036-02-29 | Start Trial |
| Fenebrutinib | Brazil | BR112018069530 | 2036-02-29 | Start Trial |
| Fenebrutinib | Canada | CA2997859 | 2036-02-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
